虚拟远像装置在近视防控中的研究进展
Research Progress of Virtual Distant Viewing Device in Myopia Prevention and Control
摘要: 虚拟远像装置(virtual distant viewing device, VDVD)基于数字光学重构技术,通过模拟4~8米等效视距场景,在近视防控中展现出多维度调控作用。其核心机制包括:(1) 光谱–神经调控:450~480 nm短波长光可激活自感光视网膜神经节细胞(ipRGC),通过黑视蛋白(melanopsin)信号通路调控视网膜多巴胺释放,进而影响脉络膜厚度;(2) 动态视标运动(0.5~1.2 Hz)维持睫状肌微波动(0.25~0.75 D),减少调节滞后;(3) 激活eNOS/cGMP通路提升脉络膜血流灌注,延缓巩膜缺氧性改变。临床研究显示,规范应用可使近视进展减缓58% (等效球镜变化干预组−0.38 D/y vs. 对照组−0.91 D/y,P < 0.001),联合抗VEGF治疗可能通过改善脉络膜微环境协同增效,但目前仍需临床试验验证,为病理性近视管理提供新思路。本文整合21项关键研究(含3项多中心RCT),通过“光学离焦–神经信号传导–组织重塑”多维作用机制的系统分析,阐明VDVD的近视调控路径,为优化近视精准防控策略提供新理论依据。
Abstract: The virtual distant viewing device (VDVD), based on digital optical reconstruction technology, demonstrates multidimensional regulatory effects in myopia prevention and control by simulating 4~8 meters equivalent viewing distance scenarios. Its core mechanisms include: (1) Spectral-Neural Modulation: Short-wavelength light (450~480 nm) activates intrinsically photosensitive retinal ganglion cells (ipRGCs) via the melanopsin signaling pathway, regulating retinal dopamine release and subsequently influencing choroidal thickness; (2) Dynamic Visual Target Motion (0.5~1.2 Hz): Maintaining ciliary muscle microfluctuations (0.25~0.75 D), reducing accommodative lag; (3) Activation of the eNOS/cGMP Pathway: Enhancing choroidal blood flow perfusion, thereby delaying hypoxia-induced scleral remodeling. Clinical studies indicate that standardized application of VDVD can slow myopia progression by 58% (spherical equivalent change: intervention group −0.38 D/y vs. control group −0.91 D/y, P < 0.001). Combined use with anti-VEGF therapy may synergistically improve choroidal microenvironments, though clinical trials are still needed for validation, offering novel insights into pathologic myopia management. This review integrates 21 key studies (including 3 multicenter RCTs) and systematically analyzes the multidimensional mechanisms of “optical defocus, neural signal transduction, and tissue remodeling” to elucidate the myopia regulatory pathways of VDVD, providing new theoretical foundations for optimizing precision myopia control strategies.
文章引用:祝荣芯, 李华. 虚拟远像装置在近视防控中的研究进展[J]. 临床医学进展, 2025, 15(4): 951-957. https://doi.org/10.12677/acm.2025.1541017

参考文献

[1] Holden, B.A., Fricke, T.R., Wilson, D.A., Jong, M., Naidoo, K.S., Sankaridurg, P., et al. (2016) Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology, 123, 1036-1042. [Google Scholar] [CrossRef] [PubMed]
[2] 国家疾病预防控制局. 儿童青少年近视防控适宜技术指南(2023修订版) [M]. 北京: 人民卫生出版社, 2023.
[3] Zhao, F., Zhang, D., Zhou, Q., Zhao, F., He, M., Yang, Z., et al. (2020) Scleral HIF-1α Is a Prominent Regulatory Candidate for Genetic and Environmental Interactions in Human Myopia Pathogenesis. EBioMedicine, 57, Article ID: 102878. [Google Scholar] [CrossRef] [PubMed]
[4] 杨孟帆, 吕莎, 李华. 光学离焦对脉络膜结构的影响研究进展[J]. 中华眼视光学与视觉科学杂志, 2024, 26(4): 317-320.
[5] Chakraborty, R., Landis, E.G., Mazade, R., Yang, V., Strickland, R., Hattar, S., et al. (2022) Melanopsin Modulates Refractive Development and Myopia. Experimental Eye Research, 214, Article ID: 108866. [Google Scholar] [CrossRef] [PubMed]
[6] Summers Rada, J.A., Shelton, S. and Norton, T.T. (2006) The Sclera and Myopia. Experimental Eye Research, 82, 185-200. [Google Scholar] [CrossRef] [PubMed]
[7] Zhen, Y., Wang, N.L., et al. (2024) Effects of Virtual Distant Viewing Technology on Preventing Nearwork-Induced Ocular Parameter Changes. Digital Health, 10. [Google Scholar] [CrossRef] [PubMed]
[8] 中华医学会眼科学分会. 中国儿童青少年近视防控指南(2023版) [J]. 中华眼科杂志, 2023, 59(6): 401-408.
[9] Gwiazda, J.E., Hyman, L., Norton, T.T., Hussein, M.E.M., Marsh-Tootle, W., Manny, R., et al. (2004) Accommodation and Related Risk Factors Associated with Myopia Progression and Their Interaction with Treatment in COMET Children. Investigative Opthalmology & Visual Science, 45, 2143-2151. [Google Scholar] [CrossRef] [PubMed]
[10] Ohno-Matsui, K., Lai, T.Y.Y., Lai, C. and Cheung, C.M.G. (2016) Updates of Pathologic Myopia. Progress in Retinal and Eye Research, 52, 156-187. [Google Scholar] [CrossRef] [PubMed]
[11] He, M., Xiang, F., Zeng, Y., Mai, J., Chen, Q., Zhang, J., et al. (2015) Effect of Time Spent Outdoors at School on the Development of Myopia among Children in China: A Randomized Clinical Trial. JAMA, 314, 1142-1148. [Google Scholar] [CrossRef] [PubMed]
[12] Lam, C.S.Y., Tang, W.C., Tse, D.Y., Lee, R.P.K., Chun, R.K.M., Hasegawa, K., et al. (2019) Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses Slow Myopia Progression: A 2-Year Randomised Clinical Trial. British Journal of Ophthalmology, 104, 363-368. [Google Scholar] [CrossRef] [PubMed]
[13] Troilo, D., Smith, E.L., Nickla, D.L., Ashby, R., Tkatchenko, A.V., Ostrin, L.A., et al. (2019) IMI—Report on Experimental Models of Emmetropization and Myopia. Investigative Opthalmology & Visual Science, 60, M31-M88. [Google Scholar] [CrossRef] [PubMed]
[14] Yao, H., Liao, Y., Lingley, A.R., et al. (2016) A Contact Lens with Embedded Sensor for Monitoring Tear Glucose. Biosensors and Bioelectronics, 82, 8-16.
[15] Torii, H., Kurihara, T., Seko, Y., Negishi, K., Ohnuma, K., Inaba, T., et al. (2017) Violet Light Exposure Can Be a Preventive Strategy against Myopia Progression. EBioMedicine, 15, 210-219. [Google Scholar] [CrossRef] [PubMed]
[16] Read, S.A., Collins, M.J. and Vincent, S.J. (2015) Light Exposure and Eye Growth in Childhood. Investigative Opthalmology & Visual Science, 56, 6779-6787. [Google Scholar] [CrossRef] [PubMed]
[17] Ma, L., Li, X., Hu, J., Li, Y., Wang, S., Wang, K., et al. (2023) Influence of a Long-Distance Optical Imaging Workbench on Accommodation and Choroidal Response in Myopic Children. Clinical and Experimental Optometry, 107, 420-427. [Google Scholar] [CrossRef] [PubMed]
[18] Baird, P.N., Saw, S., Lanca, C., Guggenheim, J.A., Smith III, E.L., Zhou, X., et al. (2020) Myopia. Nature Reviews Disease Primers, 6, Article No. 99. [Google Scholar] [CrossRef] [PubMed]
[19] Chia, A., Chua, W., Cheung, Y., Wong, W., Lingham, A., Fong, A., et al. (2012) Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2). Ophthalmology, 119, 347-354. [Google Scholar] [CrossRef] [PubMed]
[20] Jonas, J.B., Ang, M., Cho, P., Guggenheim, J.A., He, M.G., Jong, M., et al. (2021) IMI Prevention of Myopia and Its Progression. Investigative Opthalmology & Visual Science, 62, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[21] 国家药品监督管理局医疗器械技术审评中心. 近视防控光学矫正设备临床评价技术审查指导原则[M]. 北京: 中国医药科技出版社, 2021.